4:45 PM Shifting Toward Treating Kidney Diseases Rather than Treating the Consequences of Kidney Diseases
Time: 4:45 pm
day: Conference Day 1
Details:
- The new molecules being developed with kidney indications have shifted focus.
- Surrogate endpoints such as eGFR change, eGFR slope and proteinuria are innovating the treatment of kidney disease
- Voclosporin is a “real life” example of the use of surrogate endpoints and has changed the standard when treating lupus nephritis
- The impact of proteinuria reduction should not be underestimated, including to levels below what is recommended by guidelines
